New drug combo aims to make bone marrow transplants safer for older aplastic anemia patients
NCT ID NCT06752694
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether adding the drug ruxolitinib to standard care can prevent graft-versus-host disease (GVHD) in older adults with acquired aplastic anemia who receive a bone marrow transplant. GVHD is a common and serious complication where donor immune cells attack the recipient's body. The study enrolls patients over 40 or those unable to tolerate standard treatments, and aims to see if this approach lowers the risk of moderate to severe GVHD.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Ruxolitinib
- What this could lead to
- If successful, this could offer a safer way for older adults with aplastic anemia to receive a bone marrow transplant with a lower risk of serious graft-versus-host disease.
- What could go wrong
- This is a very early phase 2 trial with only one participant enrolled so far, so results are highly preliminary. Ruxolitinib may not reduce GVHD as hoped, and there are always risks of infection or other side effects from the drug and transplant.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACQUIRED APLASTIC ANEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a drug revive blood cell production in children with aplastic anemia?
- Could a platelet-boosting drug shorten recovery after stem cell transplants?
- A common antioxidant may help platelets recover faster after stem cell transplant
- Could a cancer antibody reboot blood production in aplastic anemia?
- Triple therapy aims to overcome antibody barrier in Half-Matched stem cell transplants
- New transplant method aims to reduce complications in bone marrow failure patients